中医临床研究
中醫臨床研究
중의림상연구
CLINICAL JOURNAL OF CHINESE MEDICINE
2015年
19期
14-16
,共3页
肺源性心脏病%心力衰竭%参麦注射液%红花注射液%临床疗效
肺源性心髒病%心力衰竭%參麥註射液%紅花註射液%臨床療效
폐원성심장병%심력쇠갈%삼맥주사액%홍화주사액%림상료효
Pulmonary heart disease%Heart failure%The Shenmai injection%The Honghua injection%Clinical efficacy
目的:探讨参麦注射液与红花注射液联合治疗肺源性心脏病急性发作并心力衰竭的临床疗效.方法:将我院在2010年5月-2013年5月收治的156例肺源性心脏病急性发作并心力衰竭患者,随机均分为观察组和对照组,每组各78例.对照组患者采用西医常规治疗方法,观察组患者在西医常规治疗的基础上采用静脉滴注参麦注射液和红花注射液进行治疗,比较分析两组患者的临床效果.结果:经治疗后,观察组总有效率(89.74%)显著高于对照组的总有效率(73.08%),两组间差异极显著(x2=7.1583,P<0.01);同时,观察组患者的血浆黏度、纤维蛋白原和红细胞压积水平均显著低于对照组,两组间差异极显著(分别t=49.8538、25.1266、39.4892,均P<0.01),结果具有统计学意义.结论:在常规西医治疗的基础上加用参麦注射液和红花注射液治疗肺源性心脏病急性发作并心力衰竭疗效显著,不良反应少,安全可靠,值得在临床推广使用.
目的:探討參麥註射液與紅花註射液聯閤治療肺源性心髒病急性髮作併心力衰竭的臨床療效.方法:將我院在2010年5月-2013年5月收治的156例肺源性心髒病急性髮作併心力衰竭患者,隨機均分為觀察組和對照組,每組各78例.對照組患者採用西醫常規治療方法,觀察組患者在西醫常規治療的基礎上採用靜脈滴註參麥註射液和紅花註射液進行治療,比較分析兩組患者的臨床效果.結果:經治療後,觀察組總有效率(89.74%)顯著高于對照組的總有效率(73.08%),兩組間差異極顯著(x2=7.1583,P<0.01);同時,觀察組患者的血漿黏度、纖維蛋白原和紅細胞壓積水平均顯著低于對照組,兩組間差異極顯著(分彆t=49.8538、25.1266、39.4892,均P<0.01),結果具有統計學意義.結論:在常規西醫治療的基礎上加用參麥註射液和紅花註射液治療肺源性心髒病急性髮作併心力衰竭療效顯著,不良反應少,安全可靠,值得在臨床推廣使用.
목적:탐토삼맥주사액여홍화주사액연합치료폐원성심장병급성발작병심력쇠갈적림상료효.방법:장아원재2010년5월-2013년5월수치적156례폐원성심장병급성발작병심력쇠갈환자,수궤균분위관찰조화대조조,매조각78례.대조조환자채용서의상규치료방법,관찰조환자재서의상규치료적기출상채용정맥적주삼맥주사액화홍화주사액진행치료,비교분석량조환자적림상효과.결과:경치료후,관찰조총유효솔(89.74%)현저고우대조조적총유효솔(73.08%),량조간차이겁현저(x2=7.1583,P<0.01);동시,관찰조환자적혈장점도、섬유단백원화홍세포압적수평균현저저우대조조,량조간차이겁현저(분별t=49.8538、25.1266、39.4892,균P<0.01),결과구유통계학의의.결론:재상규서의치료적기출상가용삼맥주사액화홍화주사액치료폐원성심장병급성발작병심력쇠갈료효현저,불량반응소,안전가고,치득재림상추엄사용.
Objective: To investigate the Shenmai injection and the Honghua injection for acute pulmonary heart attack plus heart failure. Methods: 156 cases of acute pulmonary heart disease were randomly divided into the observation group and the control group, 78 cases in each group. In the control group they were treated with conventional western medicine treatment, patients in the observation group were given the Shenmai injection and the Honghua injection treatment. Results: After treatment, the total efficiency in the observation group (89.74%) was significantly higher than the overall response rate (73.08%), the difference between two groups was significant (x2 = 7.1583,P<0.01); at the same time, in the observation group, plasma viscosity, fibrinogen and hematocrit water were significantly lower than those in the control group, the difference was significant (respectivelyt = 49.8538,25.1266,39.4892, allP<0.01). Conclusion: The Shenmai injection plus the Honghua injection for acute pulmonary heart attack can make significant effect on heart failure, with little adverse reactions, is safe, reliable, and worthy of clinical application.